Article information
Full text is only aviable in PDF
Bibliografía
[1.]
D.J. Balfour.
Neural mechanisms underlying nicotine dependence.
Addiction, 89 (1994), pp. 1419-1423
[2.]
G. Di Chiara, A. Imperato.
Drugs abuse by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
Proc Natl Acad Sci, 85 (1988), pp. 5274-5278
[3.]
W.A. Corrigall, K. Coen, K. Adamson.
Self administered nicotine activates the mesolimbic, dopamine system through the ventral tegmental area.
Brain Res, 653 (1994), pp. 278-284
[4.]
F.E. Pointieri, G. Tanda, F. Orzi, G. Di Chiara.
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Nature, 382 (1996), pp. 255-257
[5.]
P. Kalivas, B. Sorg, M. Hooks.
The pharmacology and neural circuit of sensitization to psychostimulants.
Behav Pharmacol, 4 (1993), pp. 315-334
[6.]
M. Benwell, D. Balfour.
The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity.
Br J Pharmacol, 105 (1992), pp. 849-856
[7.]
N. Benowitz.
Pharmacology of nicotine: addiction and therapeutics.
Annu Rev Pharmacol Toxicol, 36 (1996), pp. 597-613
[8.]
Grupo de trabajo de tratamiento del tabaquismo Separ.
Normativa para el tratamiento del tabaquismo.
Arch Bronconeumol, 35 (1999), pp. 499-506
[9.]
J. Anderson, D. Joremby, W. Scott, M. Fiore.
Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation.
Chest, 121 (2002), pp. 932-941
[10.]
I. Nerín, A. Crucelagui, A. Mas, D. Guillén.
Perfil de los fumadores que solicitan tratamiento en una unidad de tabaquismo Arch Bronconeumol, 93 (2003), pp. 298-302
[11.]
National Institute for Clinical Excellence (London).
Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation,
[12.]
A. Pérez Trullén, M. Clemente.
Estado actual y futuras terapias farmacológicas en la deshabituación tabáquica.
Arch Bronconeumol, 37 (2001), pp. 184-196
[13.]
S. Gourlay, N. Benowitz.
Is clonidine an effective smoking cessation therapy?.
Drugs, 50 (1995), pp. 197-207
[14.]
L.F. Stead, J.R. Hughes.
Lobeline for smoking cessation (Cochrane Review).
Cochrane Library, pp. 2
[15.]
T. Eissemberg, R. Griffiths, M. Stitzer.
Mecamylamine does not precipitate withdrawal in cigarette smokers.
Psychopharmacology, 127 (1996), pp. 328-336
[16.]
T. Lancaster, L. Stead.
Individual behavioural counselling for smoking cessation (Cochrane Review).
The Cochrane library, 2,
[17.]
L. Stead, T. Lancaster.
Group behavioural therapy programmes for smoking cessation (Cochrane Review).
The Cochrane library, 2,
[18.]
A US Public Health Service Report.
A clinical practice guideline for treating tobacco use and dependence.
Jama, 283 (2000), pp. 3244-3254
[19.]
J.A. Ascher, J.O. Cole, J.P. Feighner, R.M. Ferris, H.C. Fibiger, R.N. Golden.
Bupropion: a review of its mechanism of antidepressant activity.
J Clin Psychiatry, 56 (1995), pp. 395-401
[20.]
D.J. Balfour.
The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion.
Int J Clin Pract, 55 (2001), pp. 53-57
[21.]
R.D. Hurt, D.P. Sachs, E.D. Glover, K.P. Offord, J.A. Johnston, L.C. Dale, et al.
A comparison of sustained-release bupropion and placebo for smoking cessation.
N Engl J Med, 337 (1997), pp. 1195-1202
[22.]
D.E. Jorenby, S.J. Leischow, M.A. Nides, S.I. Rennard, J.A. Johnston, A.R. Hughes, et al.
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
N Engl J Med, 340 (1999), pp. 685-691
[23.]
P. Tonnesen, S. Tonstad, A. Hjalmarson, F. Lebargy, P. Van Spiegel, A. Hider, et al.
A multicentre, randomized, double-blind, placebo- controlled, 1 year study of bupropion for smoking cessation.
J Intern Med, 254 (2003), pp. 184-192
[24.]
I. Sampablo Lauro, L. Lores, F. Coll, P. Rabasa.
Asociación de bupropión y parches de nicotina como terapia para dejar de fumar.
Arch Bronconeumol, 36 (2000), pp. 377-380
[25.]
A. Tripathi, P.A. Greenberger.
Bupropion hydrochloride induced serum sickness-like reaction.
Ann Allergy Asthma Inmmunol, 83 (1999), pp. 165-166
[26.]
C.A. Patten, T.A. Rummans, I.T. Croghan, R.D. Hurt, J.T. Hays.
Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports.
J Clin Psychiatry, 60 (1999), pp. 436-441
[27.]
M. Durcan, G. Deener, J. White, J. Johnston, D. Gonzales, R. Niaura, et al.
The effect of bupropion sustained-release on cigarette craving after smoking cessation.
Clin Ther, 24 (2002), pp. 540-551
[28.]
L. Dale, E. Glover, D. Sachs, D. Schroeder, K. Offord, I. Croghan, et al.
Bupropion to smoking cessation.
Chest, 119 (2001), pp. 1357-1364
[29.]
I. Sampablo Lauro, J.M. Carreras, L. Lores, M. Quesada, F. Coll, L. Sánchez Agudo.
Deshabituación tabáquica y bupropión: la ansiedad y la depresión como índices de eficacia terapéutica.
Arch Bronconeumol, 38 (2002), pp. 351-355
[30.]
J.E. Henningfield, K. Miyasato, D.R. Jasinski.
Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine.
J Pharmacol Exp Ther, 234 (1985), pp. 1
[31.]
N.L. Benowitz.
Pharmacokinetic considerations in understanding nicotine dependence.
Ciba Found Symp, 152 (1990), pp. 186
[32.]
American Psychiatric Association.
Diagnostic and statistical manual of mental disorders,
[33.]
M.C. Fine, W.C. Bailey, S.J. Cohen, S. Dorfman, M.G. Goldstein, E.R. Gritz.
Treating tobacco use and dependence.
Clinical practice guideline,
[34.]
A.M. Joseph, S.M. Norman, L.H. Ferry, et al.
The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.
N Engl J Med, 335 (1996), pp. 1792
[35.]
Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease.
Nicotine replacement therapy for patients with coronary artery disease.
Arch Intern Med, 154 (1994), pp. 989
[36.]
R.P. Murray, W.C. Bailey, K. Daniels, et al.
Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group.
Chest, 109 (1996), pp. 438
[37.]
S.E. Kimmel, J.A. Berlin, C. Miles, et al.
Risk of acute first myocardial infarction and use of nicotine patches in a general population.
J Am Coll Cardiol, 37 (2001), pp. 1297
[38.]
N.L. Benowitz.
Nicotine replacement therapy during pregnancy.
Jama, 166 (1991), pp. 3174-3177
[39.]
R. Wisberg, T. Hensikan, N. Jespersen Ljorgen.
Nicotine patches for pregnant smokers. A randomised controlled study.
Obstet Gynecol, 96 (2000), pp. 967-971
[40.]
K.O. Fageström, R. Tejding, A. Westein, E. Lunell.
Aiding reduction of smoking with nicotine replacement medications.
Hope for the recalcitrant smokers? Tobacco Control, 6 (1997), pp. 311-316
[41.]
L. Dale, R. Hurt, K. Offord, G. Lawson, I. Croghan, D. Shroeder.
High dose nicotine patch therapy: percentage of replacement and smoking cessation.
Jama, 274 (1995), pp. 1353-1358
[42.]
T. Piasecki, T. Baker.
Any further progress in smoking cessation treatment?.
Nicotine Tob Res, 3 (2001), pp. 311
[43.]
K.O. Fageström.
Combined use of nicotine replacement products.
Health Values, 18 (1994), pp. 15-20
[45.]
P. Hajek, R. West, J. Foulds, et al.
Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler.
Arch Intern Med, 159 (1999), pp. 2033
[46.]
T. Lancaster, L. Stead, C. Silagy, A. Sowden.
Effectiveness of interventions to help people stop smoking: findings from the cochrane library.
Bmj, 321 (2000), pp. 355
[47.]
T. Blondal.
Contolled trial of nicotine polacrilex gum with supportive measures.
Arch Intern Med, 149 (1989), pp. 1818
[48.]
E.D. Glover, D.P.L. Sachs, M.L. Stitzer, et al.
Smoking cessation in highly dependent smokers with 4 mg nicotine polacrilex.
Am J Health Behavior, 20 (1996), pp. 319
[49.]
C. Silagy, T. Lancaster, L. Stead, D. Mant, G. Fowler.
Nicotine replacement therapy for smoking cessation (Cochrane database of systematic reviews).
The Cochrane Library,
[50.]
J. Hughes, D. Hatsukami.
Signs and symptoms of tobacco withdrawal.
Arch Gen Psychiatry, 43 (1986), pp. 289-294
[51.]
P. Tonnesen, V. Fryd, M. Hansen, J. Heldsted, A.B. Gunnersen, H. Forchammer.
Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomised controlled trial with a 22 month follow-up.
Addict Behav, 13 (1988), pp. 17-27
[52.]
N. Herrera, R. Franco, L. Herrera, A. Partidas, R. Rolando, K.O. Fageström.
Nicotine gum, 2 and 4 mg. for nicotine dependence. A double blind placebo controlled trial within a behavior modification support program.
Chest, 108 (1995), pp. 447-451
[53.]
M. Kortnitzer, F. Kittel, M. Dramaix, P. Bourdoux.
A double blind study of 2 mg versus 4 mg nicotine gum in an industrial setting.
J Psychosom Res, 31 (1987), pp. 171-176
[54.]
W. Lam, P.C. Sze, H.S. Sacks, T.C. Chalmers.
Meta-analysis of randomised controlled trials of nicotine chewing-gum.
Lancet, 2 (1987), pp. 27
[55.]
Pharmacia and Upjohn.
Summary of product characteristic for nicorette sublingual tablet 2 mg, (1998),
[56.]
S. Shiffman, C.M. Dresler, P. Hajek, et al.
Efficacy of a nicotine lozenge for smoking cessation.
Arch Intern Med, 162 (2002), pp. 1267
[57.]
M.C. Fiore, D.E. Jorenby, T.B. Baker.
Tobacco dependence and the nicotine patch. Clinical guidelines for effective use.
Jama, 268 (1992), pp. 2687
[58.]
Transdermal Nicotine Study Group.
Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials.
Jama, 266 (1991), pp. 3133
[59.]
N. Herrera, R. Franco, L. Herrera, A. Partidas, R. Rolando, K.O. Fagerström.
Nicotine gum, 2 and 4 mg. for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program.
Chest, 108 (1995), pp. 447-451
[60.]
P. Pusha, H. Korhonen, E. Vartiainen.
Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia.
Tob Control, 4 (1995), pp. 231-235
[61.]
D.E. Hilleman, S.M. Mohiuddin, M.G. Delcore.
Comparison of fixed- dose transdermal nicotine, tapered dose transdermal nicotine, and buspirone in smoking cessation.
J Clin Pharmacol, 34 (1994), pp. 222-224
[62.]
M.A.H. Russel, J.A. Stapleton, C. Feyerabend, S.M. Wiseman, G. Gustavsson, U. Sawe, et al.
Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches.
Bmj, 306 (1993), pp. 1308-1312
[63.]
S. Shiffman, C.A. Elash, S.M. Paton, C.J. Gwaltney, J.A. Paty, D.B. Clark.
Comparative efficacy of 24 hour and 16 hour transdermal nicotine patches for relief of morning craving.
Addiction, 95 (2000), pp. 1185-1195
[64.]
R.L. Richmond, L. Kehow, A.C. De Almeida Neto.
Three year continuous abstinence in a smoking cessation study using the nicotine transdermal patch.
Heart, 78 (1997), pp. 617
[65.]
D.M. Daughton, S.P. Fortmann, E.D. Glover, et al.
The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day.
Prev Med, 28 (1999), pp. 113
[66.]
J.R. Hughes, G.R. Lesmes, D.K. Hatsukami, R.L. Richmond, E. Lichstenstein, D.E. Jorenby.
Are higher doses of nicotine replacement more effective for smoking cessation?.
Nicotine Tob Res, 1 (1999), pp. 169-174
[67.]
L.C. Dale, R.D. Hurt, K.P. Offord, G.M. Lawson, I.T. Croghan, D.R. Schroeder.
High-dose nicotine patch therapy – percentage of replacement and smoking cessation.
Jama, 274 (1995), pp. 1353-1358
[68.]
D.E. Jorenby, S.S. Smith, M.C. Fiore, R.D. Hurt, K.P. Offord, I.T. Crogham.
Varying nicotine patch dose and type of smoking cessation counselling.
Jama, 274 (1995), pp. 1347-1352
[69.]
P. Tonnesen, P. Paoletti, G. Gustavsson, M.A. Russell, R. Saracci, A. Gulsvik.
Higher dosage nicotine patches increase one year smoking cessation rates. Results from the European CEASE trial.
Eur Respir J, 13 (1999), pp. 238-246
[70.]
J.D. Killen, S.P. Fortmann, L. Davis, L. Strausberg, A. Varady.
Do heavy smokers benefit fronm higher dose nicotine patch therapy?.
Exp Clin Psychopharmacol, 7226 (1999), pp. 233
[71.]
P. Paoletti, E. Fornai, F. Maggiorelli, R. Puntoni, G. Viegi, L. Carrozzi.
Importance of baseline cotinine plasma values in smoking cessation: results from a double blind study with nicotine patch.
Eur Respir J, 9 (1996), pp. 643-651
[72.]
J.R. Hughes, M.G. Goldstein, R.D. Hurt, S. Shiffman.
Recent advances in the pharmacotherapy of smoking.
Jama, 281 (1999), pp. 72
[73.]
N.S. Nicotrol.
Product Information.
Physician's Desk reference 1998,
[74.]
J.A. Stapleton, G. Sutherland, M. Russell.
How much does relapse after one year erode effectivenes of smoking cessation treatments? Long term follow up randomised trial of nicotine nasal spray.
Br Med J, 316 (1998), pp. 830-831
[75.]
C.A. Jiménez Ruiz, S. Flórez, A. Ramos, J.J. Lorza, M.A. Hernández- Mezquita, S. Solano Reina, et al.
Tratamiento del tabaquismo con nebulizador nasal de nicotina. Resultados de un estudio multicéntrico.
Arch Bronconeumol, 35 (1999), pp. 535-538
[76.]
J.E. Rose, E.D. Levin.
Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence.
Pharmacol Biochem Behav, 41 (1991), pp. 219-226
[77.]
S.J. Leischow, F. Nilsson, M. Franzon, F.V. Mody, M. Franzon, K. Doan.
Efficacy of the nicotine inhaler as an adjunct to smoking cessation.
Am J Health Behav, 20 (1996), pp. 364-371
[78.]
N.G. Schneider, R. Olmstead, F. Nilsson, F.V. Mody, M. Franzon, K. Doan.
Efficacy of nicotine inhaler in smoking cessation: a double blind placebo controlled trial.
Addiction, 91 (1996), pp. 1293-1306
[79.]
P. Pentel, D. Malin, S. Ennifar, Y. Hieda, D. Keyler, J. Lake, et al.
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioural and cardiovascular effects in rats.
Pharmacol Biochem Beha, 65 (2000), pp. 191-198
[80.]
S. De Villiers, N. Lindblom, G. Kalayanov, S. Gordon, A. Malmerfelt, A. Johansson, et al.
Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell.
Respiration, 69 (2002), pp. 247-253
[81.]
N. Lindblom, S. De Villiers, G. Kalayanov, S. Gordon, A. Johansson, T. Svensson.
Active immunization against nicotine prevents reinstatement of nicotine-seeking behaviour in rats.
Respiration, 69 (2002), pp. 254-260
[82.]
N.L. Benowitz, P. Jacob.
Metabolism of nicotine to cotinine studied by a dual stable isotope method.
Clin Pharmacol Ther, 56 (1994), pp. 483-493
[83.]
X. Chun, S. Goodz, E.M. Sellers, R.F. Tyndale.
CYP2A6 genetic variation and potential consequences.
Adv Drug Deliv Rev, 54 (2002), pp. 1245-1256
[84.]
Y. Rao, E. Hoffmann, M. Zia, L. Bodin, M. Zeman, E.M. Sellers, et al.
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
Mol Pharmacol, 58 (2000), pp. 747-755
[85.]
E.M. Sellers, R.F. Tyndale, L.C. Fernandes.
Decreasing smoking behaviour and risk through CYP2A6 inhibition.
Doug Discov Today, 8 (2003), pp. 487-493
[86.]
D.F. Gu, L.J. Hinks, N.E. Morton, I.N.M. Day.
The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit.
Am Hum Genet, 64 (2000), pp. 383-390
[87.]
E.M. Sellers, H.L. Kaplan, R.F. Tyndale.
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.
Clin Pharmacol Ther, 68 (2000), pp. 35-43
[88.]
J. Norregaard, S. Jorgensen, K.L. Mikkelsen.
The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain.
Clin Pharmacol Ther, 60 (1996), pp. 679-686
[89.]
S.G. Gourlay, N.L. Benowitz.
Is clonidine an effective smoking cessation therapy?.
Drugs, 50 (1995), pp. 197-207
[90.]
M. Law, J.L. Tang.
An analysis of the effectiveness of interventions intended to help people stop smoking.
Arch Intern Med, 155 (1995), pp. 1933-1941
[91.]
L.S. Covey, A.H. Glassman.
A meta-analysis of double-blind placebo- controlled trials of clonidine for smoking cessation.
Br J Addict, 86 (1991), pp. 991-998
[92.]
US Department of Health and human Services.
Clinical practice guideline smoking cessation,
[93.]
G. Sutherland, J.A. Stapleton, M.A. Russell, C. Feyerband.
Naltrexone, smoking behavior and cigarette withdrawal.
Psycopharmacology, 120 (1995), pp. 418-425
[94.]
G. Humfleet, S. Hall, V. Reus, K. Sees, R. Muñoz, E. Triffleman.
The efficacy of nortriptyline as an adjunct to psychological treatment for smokers with and without depression histories.
Problems of drug dependence 1995: Proceedings of the 57th Annual Scientific Meeting of the College on Problems of drug dependence, Inc. NDA Research monograph 162,
[95.]
J.K. Murphy, N.B. Edwards, A.D. Downs.
Effects of doxepin on withdrawal symptoms in smoking cessation.
Am J Psychiatry, 147 (1990), pp. 1353-1357
[96.]
N.B. Edwards, R.C. Simmons, T.L. Rosenthal.
Doxepin in the treatment of nicotine withdrawal.
Psychosomatic, 29 (1988), pp. 203-206
[97.]
J.R. Hughes.
Non nicotine pharmacotherapies for smoking cessation.
J Drug Dev, 6 (1994), pp. 197-203
[98.]
J.S. Fowler, N.D. Volknow, G.J. Wang.
Inhibition of monoamine oxidase B in the braims of smokers.
Nature, 379 (1996), pp. 733-737
[99.]
T.P. George, J.C. Vessicchio, A. Termine, P.I. Jatlow, T.R. Kosten, S.S. O'Malley.
A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation.
Biol Psichy, 53 (2003), pp. 136-143
[100.]
I. Berlin, S. Said, O. Spreux-Varoquaux.
A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation cessation and abstinence in heavy dependent smokers.
Clin Pharmacol Ther, 58 (1995), pp. 444-452
[101.]
B. Hitsman, R. Pingitore, B. Spring, A. Mahableshwarkar, J.S. Mizes, K.A. Segraves, et al.
Antidepressant pharmacotherapy helps some cigarette smokers more than others.
J Consult Clin Psychol, 67 (1999), pp. 547-554
[102.]
P.M. Cinciripini, L. Lapitsky, S. Seay, A. Wallfish, W.J. Meyer, H. Van Vunakis.
A placebo-controlled evaluation of the effects of buspirone on smoking vessation: differences between high and low anxiety smokers.
J Clin Psichopharmacol, 15 (1995), pp. 182-191
[103.]
J.E. Rose, F.M. Behm.
Inhalation of vapor from black peper extrat reduces smoking withdrawal symptoms.
Drug Alcohol Depend, 34 (1994), pp. 225-229
[104.]
R. Malcolm.
Silver acetate gum as a smoking deterrent.
Chest, 89 (1986), pp. 107-111
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica
